SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2025
0mins
Should l Buy SERA?
Source: PRnewswire
Company Presentation Announcement: Sera Prognostics Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, where CEO Zhenya Lindgardt will discuss the company's achievements.
Focus on Maternal and Neonatal Health: The company aims to enhance maternal and neonatal health through innovative pregnancy biomarker information, particularly with their PreTRM® Test that predicts preterm birth risk.
Preterm Birth Statistics: Preterm birth is a significant health issue in the U.S., affecting over 10% of infants annually and leading to long-term medical complications and substantial healthcare costs.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future events and risks, emphasizing uncertainties related to revenue, market acceptance, and regulatory factors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SERA
Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.920
Low
5.00
Averages
5.00
High
5.00
Current: 1.920
Low
5.00
Averages
5.00
High
5.00
About SERA
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sera Prognostics 2025 Financial Report Analysis
- Revenue Fluctuation: In Q4 2025, revenue dropped to $10,000 from $24,000 in Q4 2024, indicating significant volatility at this early commercial stage, which may affect investor confidence.
- High Operating Expenses: Operating expenses for Q4 stood at $9 million, down from $9.4 million in the previous year, yet still reflect the high costs associated with commercialization efforts, potentially limiting profitability improvements.
- Net Loss Improvement: The net loss for Q4 2025 was $7.9 million, an improvement from $8.6 million in 2024; however, ongoing losses pose challenges to the company's financial health, impacting future funding capabilities.
- Strong Cash Reserves: By the end of 2025, the company held $95.8 million in cash equivalents, expected to fund operations through 2028, providing essential financial support for its commercialization strategy and enhancing market confidence.
See More
Sera Prognostics Q4 2025 Earnings Call Insights
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, down from $24,000 in Q4 2024, although operating expenses decreased from $9.4 million to $9 million, reflecting efforts in financial discipline.
- Leadership Enhancement: The company appointed Lee Anderson as Chief Commercial Officer and Dr. Tiffany Inglis as Chief Medical Officer, aiming to strengthen market outreach and medical affairs to drive the implementation of the PRIME project and increase market share in maternal health.
- Market Expansion Plans: Sera aims to engage in active discussions across 15 to 17 states by the end of 2026 and plans to increase the number of partner programs to cover 58% to 60% of U.S. births, indicating a proactive approach in its commercialization strategy.
- Future Outlook: Management expects gradual revenue growth as partner programs mature and emphasizes maintaining financial discipline to support significant milestones through 2028, ensuring effective capital utilization.
See More
Sera Prognostics Q4 2025 Earnings Call Transcript
See More
Sera Prognostics Reports 2025 Financial Results and Strategic Progress
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, a 58.3% decline from $24,000 in Q4 2024, indicating challenges in the commercialization process, while total annual revenue reached $81,000, up 5.2% from $77,000 in 2024, reflecting gradual market acceptance improvements.
- Cost Control: Total operating expenses for Q4 2025 were $9.0 million, down 4.3% from $9.4 million in Q4 2024, with R&D expenses at $3.2 million, slightly higher than last year's $3.1 million, indicating a balance between R&D and market promotion to support future growth.
- Net Loss: The net loss for Q4 2025 was $7.9 million, an 8.2% decrease from $8.6 million in Q4 2024, demonstrating ongoing efforts in capital management despite pressures on revenue expansion.
- Cash Flow and Financing: As of December 31, 2025, the company had approximately $95.8 million in cash and cash equivalents, expected to fund significant market adoption and commercial milestones through 2028, enhancing investor confidence in future growth.
See More
Sera Prognostics Q4 Non-GAAP EPS Beats Expectations
- Earnings Highlights: Sera Prognostics reported a Q4 Non-GAAP EPS of -$0.16, beating expectations by $0.03, indicating some resilience in profitability despite challenges.
- Revenue Decline: The company's revenue for Q4 was $0.01 million, a 50% year-over-year decrease, reflecting weak market demand and challenges that could impact future cash flow.
- Market Reaction: Despite the significant revenue drop, the better-than-expected Non-GAAP EPS may temporarily boost investor confidence and help stabilize the stock price in the short term.
- Future Outlook: The company needs to implement effective strategies to address the revenue decline challenges to restore growth and enhance market competitiveness, especially in the current economic environment.
See More
Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
See More
Sera Prognostics 2025 Financial Report Analysis
- Revenue Fluctuation: In Q4 2025, revenue dropped to $10,000 from $24,000 in Q4 2024, indicating significant volatility at this early commercial stage, which may affect investor confidence.
- High Operating Expenses: Operating expenses for Q4 stood at $9 million, down from $9.4 million in the previous year, yet still reflect the high costs associated with commercialization efforts, potentially limiting profitability improvements.
- Net Loss Improvement: The net loss for Q4 2025 was $7.9 million, an improvement from $8.6 million in 2024; however, ongoing losses pose challenges to the company's financial health, impacting future funding capabilities.
- Strong Cash Reserves: By the end of 2025, the company held $95.8 million in cash equivalents, expected to fund operations through 2028, providing essential financial support for its commercialization strategy and enhancing market confidence.
See More
Sera Prognostics Q4 2025 Earnings Call Insights
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, down from $24,000 in Q4 2024, although operating expenses decreased from $9.4 million to $9 million, reflecting efforts in financial discipline.
- Leadership Enhancement: The company appointed Lee Anderson as Chief Commercial Officer and Dr. Tiffany Inglis as Chief Medical Officer, aiming to strengthen market outreach and medical affairs to drive the implementation of the PRIME project and increase market share in maternal health.
- Market Expansion Plans: Sera aims to engage in active discussions across 15 to 17 states by the end of 2026 and plans to increase the number of partner programs to cover 58% to 60% of U.S. births, indicating a proactive approach in its commercialization strategy.
- Future Outlook: Management expects gradual revenue growth as partner programs mature and emphasizes maintaining financial discipline to support significant milestones through 2028, ensuring effective capital utilization.
See More
Sera Prognostics Q4 2025 Earnings Call Transcript
See More
Sera Prognostics Reports 2025 Financial Results and Strategic Progress
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, a 58.3% decline from $24,000 in Q4 2024, indicating challenges in the commercialization process, while total annual revenue reached $81,000, up 5.2% from $77,000 in 2024, reflecting gradual market acceptance improvements.
- Cost Control: Total operating expenses for Q4 2025 were $9.0 million, down 4.3% from $9.4 million in Q4 2024, with R&D expenses at $3.2 million, slightly higher than last year's $3.1 million, indicating a balance between R&D and market promotion to support future growth.
- Net Loss: The net loss for Q4 2025 was $7.9 million, an 8.2% decrease from $8.6 million in Q4 2024, demonstrating ongoing efforts in capital management despite pressures on revenue expansion.
- Cash Flow and Financing: As of December 31, 2025, the company had approximately $95.8 million in cash and cash equivalents, expected to fund significant market adoption and commercial milestones through 2028, enhancing investor confidence in future growth.
See More
Sera Prognostics Q4 Non-GAAP EPS Beats Expectations
- Earnings Highlights: Sera Prognostics reported a Q4 Non-GAAP EPS of -$0.16, beating expectations by $0.03, indicating some resilience in profitability despite challenges.
- Revenue Decline: The company's revenue for Q4 was $0.01 million, a 50% year-over-year decrease, reflecting weak market demand and challenges that could impact future cash flow.
- Market Reaction: Despite the significant revenue drop, the better-than-expected Non-GAAP EPS may temporarily boost investor confidence and help stabilize the stock price in the short term.
- Future Outlook: The company needs to implement effective strategies to address the revenue decline challenges to restore growth and enhance market competitiveness, especially in the current economic environment.
See More
Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
See More
